DURECT Corporation (DRRX)

NASDAQ: DRRX · IEX Real-Time Price · USD
-0.001 (-0.15%)
At close: Nov 27, 2023, 4:00 PM
-0.002 (-0.26%)
After-hours: Nov 27, 2023, 7:06 PM EST

Company Description

DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs.

The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals.

It also develops larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis.

In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine over three days in adults; and Methydur to treat attention deficit hyperactivity disorder.

It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally.

The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Innocoll Pharmaceuticals Limited.

DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.

DURECT Corporation
Country United States
Founded 1998
IPO Date Sep 28, 2000
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 72
CEO Dr. James E. Brown D.V.M.

Contact Details

10260 Bubb Rd
Cupertino, California 95014
United States
Phone (408) 777-1417
Website durect.com

Stock Details

Ticker Symbol DRRX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001082038
CUSIP Number 266605104
ISIN Number US2666055007
Employer ID 94-3297098
SIC Code 2834

Key Executives

Name Position
Dr. James E. Brown D.V.M. Co-Founder, Chief Executive Officer, President and Director
Judy R. Joice Senior Vice President of Operations and Corporate Quality Assurance
Dr. Norman L. Sussman M.D. Chief Medical Officer
Timothy M. Papp M.B.A. Chief Financial Officer and Secretary
Jian Li M.B.A. Interim Principal Accounting Officer, Senior Vice President of Finance, Corporate Controller and Secretary
Dr. Andrew R. Miksztal Ph.D. Vice President of Pharmaceutical Research & Development and Principal Scientist
Steve Helmer J.D. Vice President and Chief Patent Counsel
Dr. WeiQi Lin M.D., Ph.D. Executive Vice President of Research & Development and Principal Scientist
Keith L. Lui M.B.A. Senior Vice President of Business Development, Commercial and Medical Affairs
Dr. Su Il Yum Ph.D. Executive Officer

Latest SEC Filings

Date Type Title
Nov 14, 2023 10-Q Quarterly Report
Nov 13, 2023 8-K Current Report
Nov 7, 2023 8-K Current Report
Sep 7, 2023 8-K Current Report
Aug 10, 2023 S-8 Securities to be offered to employees in employee benefit plans
Aug 10, 2023 10-Q Quarterly Report
Aug 9, 2023 8-K Current Report
Jul 21, 2023 8-K Current Report
Jul 21, 2023 424B5 Filing
Jun 22, 2023 8-K Current Report